

AmerisourceBergen

MWI Animal Health®

Available through MWI 800.824.3703 mwiah.com

ARTHRAMIDVET®

Proven Science. Proven Results.



Stop Arthritis Where it Starts

**An Innovative Tissue Scaffold Technology
to Manage Equine Osteoarthritis**



**contura
vet**

AmerisourceBergen is not making any claims about the safety or efficacy of this product. AmerisourceBergen strongly encourages customers to review the labeling information for any product and to rely on their own clinical judgment before ordering or prescribing any product.

Since 2009, Contura® Vet has been committed to developing a state-of-the-art OA treatment for equine patients. ArthramidVet® is an injectable 2.5% polyacrylamide (iPAAG) hydrogel 20+ years in the making. With a patented, cross-linking technology, ArthramidVet® is a FDA Regulated GMP facility in Copenhagen, Denmark.

A Safe, Long-Term Approach to Managing Synovitis and OA in Horses


ArthramidVet® goes beyond conventional therapies, using a dynamic bio-scaffold technology to safely and sustainably manage osteoarthritis.¹ Patients gain increased load transfer capacity through the joint capsule, reduced effusion and decreased stiffness. Over 80% remain lame-free after one injection.²

The Synovial Membrane Matters

The cells of the synovium are responsible for the production and health of joint fluid. Joint fluid provides cushioning, reduces friction, and nourishes cartilage. If these cells become damaged, the integrity and quality of joint fluid is diminished, which can lead to inflammation within the joint space. Chronic inflammation can lead to synovitis, capsulitis, and OA.


How does ArthramidVet® work?

ArthramidVet® integrates into the synovial membrane and creates a long-term “bio-scaffold” within the synovium. This bio-scaffold supports the healthy regeneration of the synovium through the body’s normal healing process. Its unique mechanism of action strengthens the affected joint, restores function, and freedom of movement.



- Long-lasting results and sustained soundness (lame free)¹
- 83% of 2.5% iPAAG treated joints were lame free at 6w vs. 27% for TA and 40% HA (p<0.05) in a 2021 double-blinded positive control study in racing Thoroughbreds²
- Arthramid® Vet can safely be used to treat multiple joints concurrently in the same animal²

Lame free outcome at 6 weeks



J Equine Vet Sci (2021). A double blinded positive control study comparing the relative efficacy of 2.5% PAAG against triamcinolone acetonide (TA) and Sodium Hyaluronate (HA) in the management of middle carpal joint lameness in racing TB's. Available from: <https://doi.org/10.1016/j.jevs.2021.103780>

Case Selection

Cases suitable for treatment with ArthramidVet® are those in which lameness is localized to the joint by clinical examination, intra-articular analgesia, +/- radiography, ultrasound, MRI, CT, and/or Scintigraphy. The most commonly treated equine joints include knees (carpus), hocks, stifles, fetlocks, and coffin joints. Successful treatment has also been demonstrated in other synovial structures.

Conditions that respond to treatment with ArthramidVet® include acute and chronic synovitis, capsulitis, and osteoarthritis. Cases that respond well to conventional joint therapies are excellent candidates for ArthramidVet®.

Post Treatment Recommendations

As with all intra-articular injections, stall rest your horse for 48 hours immediately after treatment, with a gradual return to work.

A follow-up examination at 4-6 weeks is advised to assess the response to treatment. In horses with an observed partial response (around 15% of cases) additional treatment may be indicated, or a reassessment of the original diagnosis may be necessary.

Horses typically show a gradual reduction in lameness within the first few weeks following treatment and continue to improve over the ensuing months.

¹ Tnibar, A., Schougaard, H., Camitz, L., Rasmussen, J., Koene, M., Jahn, W., Markussen, B., An international multi-centre prospective study on the efficacy of an intrarticular polyacrylamide hydrogel in horses with osteoarthritis: a 24 month follow up. Acta Vet Scand. 2015; 57: 20-27.

² De Clifford, L.T., Lowe, J.N., McKellar, C.D., Chambers, M., David, F., A double-blinded positive control study comparing the relative efficacy of 2.5% polyacrylamide hydrogel (PAAG) against triamcinolone acetonide (TA) and sodium hyaluronate (HA) in the management of middle carpal joint lameness in racing Thoroughbreds. Journal Equine Vet Science; [epub 2021 Sept 24]

Dosing Recommendations

Distal Interphalangeal (DIP/ Coffin)	● 1-2 mLs
Metacarpo/tarso-phalangeal (Fetlock)	● 1-2 mLs
Carpus	● 1-2 mLs
Pastern	● 1-2 mLs
Cervical	● 1-2 mLs
Tarso-metatarsal (TMT)/ Distal-intertarsal (DIT)	● 1 mL
Tarsocrural	● 2-3 mLs
Shoulder	● 3 mLs
Stifles	● 1-2 mLs per compartment or (for stifle) 3-4 mLs for medial-femorotibial joint

Administration

ArthramidVet® comes in prefilled sterile 1 mL syringes, sealed via Luer lock fitting. Arthramid® Vet should be administered via a sterile 18-23g needle using the aseptic technique protocols.



Storage

ArthramidVet® must be stored protected from direct sunlight. Do not freeze. Do not store unsealed syringes for later use. ArthramidVet has a 3-year shelf life; always check package expiration date before use.

Precautions and Contraindications

Arthramid® Vet 2.5% iPAAG is safe, non-pyrogenic, and neuro innocuous. Suitable treatment cases include those in which where lameness is localized to the joint by clinical examination, intra-articular analgesia, radiography +/- ultrasound, MRI, CT, or scintigraphy.

Proper administration requires anamnesis and review of data of ongoing infection, surgery, or potential fracture before injection to prevent possible infections or product use for conditions other than indicated.

ArthramidVet® should not be injected into actively infected joints, infected surrounding joint soft tissues, or infected skin overlying the joint. No allergic reactions have been recorded to date.

Caution: Federal law restricts this prescription device to sale by or on the order of a licensed veterinarian and it must be used under the supervision of a licensed veterinarian for the application of intra-articular administration.



AVUSA2022-001 | Copyright ©2023

Manufactured by Contura International of Denmark
Marketed in the USA by Contura Vet (USA) Inc.

3401 Mallory Lane, Suite 100, Franklin, TN 37067 USA

Email: contact@conturavet.com | Call Toll Free: (800) 689-2909

CVUS-EQ-2307102